Results 21 to 30 of about 2,751,693 (208)

A Study on BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia from Western India

open access: yesAsian Pacific Journal of Cancer Biology, 2021
Background: BCR-ABL kinase domain(KD) mutations accounts for 60-80% of Imatinib resistance in chronic myeloid leukemia (CML) – chronic phase (CP). Patients with CML who are receiving imatinib treatment, a mutation analysis is required to find out the ...
Pankaj Gadhia   +4 more
doaj   +1 more source

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. [PDF]

open access: yesProc Natl Acad Sci U S A, 2021
Lyczek A   +11 more
europepmc   +2 more sources

The Potential circRNAs in Imatinib Resistance of GIST [PDF]

open access: yes, 2021
Abstract Background: Circular RNAs are a recently (re-)discovered abundant RNA species, belongs to part of the competing endogenous RNA network(ceRNA), Which was proved to play a critical role in the development, diagnosis and progress of diseases. Methods: We analyzed the expression of circular RNAs in paired normal gastric tissues(N), primary
Jingyi Yan   +4 more
openaire   +2 more sources

Antileukemic Activity of hsa-miR-203a-5p by Limiting Glutathione Metabolism in Imatinib-Resistant K562 Cells

open access: yesCurrent Issues in Molecular Biology, 2022
Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors
Priyanka Singh   +3 more
doaj   +1 more source

Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes

open access: yesCell Death and Disease, 2021
Chronic myeloid leukemia (CML) patients with complex chromosomal translocations as well as non-compliant CML patients often demonstrate short-lived responses and poor outcomes on the current therapeutic regimes using Imatinib and its variants.
Anusha   +7 more
doaj   +1 more source

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Recent studies indicate the presence of pre-existing BCR-ABL mutations in a higher percentage of CML patients ...
Zafar Iqbal   +19 more
doaj   +1 more source

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia

open access: yesBiomedicines, 2022
Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular ...
Raquel Alves   +4 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a “drug target prediction-gene microarray analysis-protein network construction” strategy

open access: yesBMC Complementary and Alternative Medicine, 2019
Background The introduction of imatinib revolutionized the treatment of chronic myeloid leukaemia (CML), substantially extending patient survival. However, imatinib resistance is currently a clinical problem for CML.
Huayao Li   +8 more
doaj   +1 more source

Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. [PDF]

open access: yesPLoS ONE, 2013
Dermatofibrosarcoma protuberans (DFSP) is a very rare soft tissue sarcoma. DFSP often reveals a specific chromosome translocation, t(17;22)(q22;q13), which results in the fusion of collagen 1 alpha 1 (COL1A1) gene and platelet-derived growth factor-B ...
Jung Yong Hong   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy